NCT04316689CompletedPhase 1
Open-label, Phase 1 Study of S-488210/S-488211 to Evaluate the Safety and Tolerability in Patients With Unresectable Recurrent and/or Metastatic Solid Tumor
Shionogi2 sites in 1 country10 target enrollmentStarted: July 30, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 10
- Locations
- 2
- Primary Endpoint
- Number of Participants with Adverse Events
Study Overview
Brief Summary
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with unresectable recurrent and/or metastatic solid tumor of lung, esophageal, head and neck, mesothelioma, or bladder cancer (including urothelial cancer of renal pelvis, ureters, and urethra), who have progressed after conventional systemic therapies or have exhausted or are intolerant to existing treatment options.
- •Human leukocyte antigen (HLA)-A*02:01-positive patients.
- •Patients who are male or female aged ≥18 years at the time of informed consent.
- •Patients with the Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 at enrollment.
- •Patients who have a lymphocyte count accounting for 15% or higher of the total white blood cell count within 28 days before enrollment.
- •Patients who provide a personally signed and dated informed consent document for participation in the study.
- •Patients with expected life-span of at least 3 months from the time of enrollment.
Exclusion Criteria
- •Patients who are expected to require any of the following therapies between enrollment and completion of the Observation Period.
- •Anti-malignant tumor drug
- •Systemic corticosteroid (except for corticosteroid defined as the equivalent of prednisone ≤ 10 mg/day orally)
- •Systemic immunosuppressant drug
- •Radiotherapy (except for restricted radiotherapy for pain relief of bone metastasis) for the cancer(s)
- •Surgical therapy for the cancer(s)
- •Hyperthermia for the cancer(s)
- •Traditional Chinese herbal medicine with anti-tumor or immunosuppressant effect
- •Other investigational products
- •Patients who have severe concurrent hepatic impairment, renal impairment, heart disease, hematological disease, respiratory disease, or metabolic disease, with the exception of any symptoms and/or signs associated with cancer(s).
- •Patients who have known human immunodeficiency virus infection.
- •Patients with uncontrolled systemic or active infection.
- •Patients who had any diseases with the risk of sudden death within 12 months before enrollment.
- •Patients with a history or evidence of autoimmune diseases and/or immunodeficiencies.
- •Female patients who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations.
- •Patients who are considered ineligible for this study by the investigator or subinvestigator due to any reasons, including inability to understand and follow the requirements of the study.
Outcomes
Primary Outcomes
Number of Participants with Adverse Events
Time Frame: Up to 16 weeks
Adverse events will be classified by system organ class and preferred term using Medical Dictionary for Regulatory Activities (MedDRA).
Secondary Outcomes
- Cytotoxic T Lymphocyte (CTL) Induction Rate(Baseline and Weeks 8 and 12)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Unknown
Phase 1
A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT04843033Nanjing Sanhome Pharmaceutical, Co., Ltd.55
Completed
Phase 1
Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) SubjectsProstatic NeoplasmsNCT02363855Bayer9
Not yet recruiting
Phase 1
A Study of BPI-452080 in Subjects With Solid TumorsSolid TumorVon Hippel-Lindau DiseaseRenal Cell CarcinomaNCT05843305Betta Pharmaceuticals Co., Ltd.87
Recruiting
Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid TumorsSolid TumorsNCT05101070Shionogi282
Completed
Phase 1
Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy AdultsHealthy VolunteerNCT04147715Shionogi98